Merck to Buy Harpoon Therapeutics for $680 Million
Merck to Buy Harpoon Therapeutics for $680 Million
Merck & Co. has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million.
Merck on Monday said it will pay $23 a share in cash for Harpoon, more than double Friday’s closing price of $10.55 for the South San Francisco, Calif., company.
Bloomberg earlier reported that Rahway, N.J.-based Merck was in talks to buy Harpoon.
Merck said the deal adds Harpoon’s HPN328, which is being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors.
Merck, which is girding for the pending 2028 loss of patent protection for its blockbuster cancer drug Keytruda, said it expects to complete the Harpoon acquisition in the first half of the year, adding that the deal will result in a charge of about $650 million, or 26 cents a share.
Harpoon shares were recently up about 110% to $22.11 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
Publication: The Wall Street Journal
Author: Colin Kellaher
Link: Merck to Buy Harpoon Therapeutics for $680 Million - WSJ
Get Updates
from LSPA
Stay up-to-date on the latest news and events from Life Sciences PA, insights from the life sciences industry, and so much more!
Life Sciences Pennsylvania was founded in 1989 by a biotech scientist at Penn State University. Today it has grown to represent the entire life sciences industry – medical device companies, pharmaceutical companies, investment organizations, research institutions, and myriad service industries that support the life sciences in Pennsylvania.